甲状旁腺激素相关肽水平与恶性肿瘤患者死亡率之间的关系。

IF 3.7 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Endocrine Practice Pub Date : 2024-12-01 DOI:10.1016/j.eprac.2024.09.003
Ai Kimura MD, Kazuhiko Kato MD, Akio Nakashima MD, PhD, Yukio Maruyama MD, PhD, Ichiro Ohkido MD, PhD, Yoichi Miyazaki MD, PhD, Takashi Yokoo MD, PhD
{"title":"甲状旁腺激素相关肽水平与恶性肿瘤患者死亡率之间的关系。","authors":"Ai Kimura MD,&nbsp;Kazuhiko Kato MD,&nbsp;Akio Nakashima MD, PhD,&nbsp;Yukio Maruyama MD, PhD,&nbsp;Ichiro Ohkido MD, PhD,&nbsp;Yoichi Miyazaki MD, PhD,&nbsp;Takashi Yokoo MD, PhD","doi":"10.1016/j.eprac.2024.09.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Hypercalcemia of malignancy is a risk factor for mortality in patients with malignancies. Although the parathyroid hormone-related protein (PTHrP) secreted by tumor cells induces hypercalcemia, the association between serum PTHrP levels and mortality remains unclear. This study aimed to investigate the association between serum PTHrP levels and mortality in patients with malignancies.</div></div><div><h3>Methods</h3><div>We included patients with hypercalcemia (&gt;10 mg/dL) and elevated PTHrP levels (&gt;1.1 pmol/L) and analyzed mortality (overall survival after cancer diagnosis, PTHrP measurement, and 5-year survival rate). Moreover, using Cox proportional hazard model analysis, we investigated the impact of PTHrP levels on survival prognosis, assessing whether this effect varied depending on calcium concentration.</div></div><div><h3>Results</h3><div>We analyzed the data of 183 patients. The median PTHrP level, corrected calcium level, and age were 5.5 (3.0-10.6) pmol/L, 12.5 (11.5-13.4) mg/dl, and 70 (61-76) years, respectively. PTHrP was significantly and linearly associated with serum calcium levels (correlation coefficient, 0.06; 95% CI: 0.039-0.081, t: 5.69; <em>P</em> &lt; .001). The group with the highest PTHrP levels had significantly worse survival rates than the group with the lowest PTHrP levels (hazard ratio: 1.68, 95% CI 1.03-2.77, <em>P</em> = .038).</div></div><div><h3>Conclusion</h3><div>This study showed an association between PTHrP and mortality in patients with malignancy after adjusting for serum calcium levels.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"30 12","pages":"Pages 1119-1125"},"PeriodicalIF":3.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association Between Parathyroid Hormone-Related Peptide Levels and Mortality in Patients With Malignancy\",\"authors\":\"Ai Kimura MD,&nbsp;Kazuhiko Kato MD,&nbsp;Akio Nakashima MD, PhD,&nbsp;Yukio Maruyama MD, PhD,&nbsp;Ichiro Ohkido MD, PhD,&nbsp;Yoichi Miyazaki MD, PhD,&nbsp;Takashi Yokoo MD, PhD\",\"doi\":\"10.1016/j.eprac.2024.09.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>Hypercalcemia of malignancy is a risk factor for mortality in patients with malignancies. Although the parathyroid hormone-related protein (PTHrP) secreted by tumor cells induces hypercalcemia, the association between serum PTHrP levels and mortality remains unclear. This study aimed to investigate the association between serum PTHrP levels and mortality in patients with malignancies.</div></div><div><h3>Methods</h3><div>We included patients with hypercalcemia (&gt;10 mg/dL) and elevated PTHrP levels (&gt;1.1 pmol/L) and analyzed mortality (overall survival after cancer diagnosis, PTHrP measurement, and 5-year survival rate). Moreover, using Cox proportional hazard model analysis, we investigated the impact of PTHrP levels on survival prognosis, assessing whether this effect varied depending on calcium concentration.</div></div><div><h3>Results</h3><div>We analyzed the data of 183 patients. The median PTHrP level, corrected calcium level, and age were 5.5 (3.0-10.6) pmol/L, 12.5 (11.5-13.4) mg/dl, and 70 (61-76) years, respectively. PTHrP was significantly and linearly associated with serum calcium levels (correlation coefficient, 0.06; 95% CI: 0.039-0.081, t: 5.69; <em>P</em> &lt; .001). The group with the highest PTHrP levels had significantly worse survival rates than the group with the lowest PTHrP levels (hazard ratio: 1.68, 95% CI 1.03-2.77, <em>P</em> = .038).</div></div><div><h3>Conclusion</h3><div>This study showed an association between PTHrP and mortality in patients with malignancy after adjusting for serum calcium levels.</div></div>\",\"PeriodicalId\":11682,\"journal\":{\"name\":\"Endocrine Practice\",\"volume\":\"30 12\",\"pages\":\"Pages 1119-1125\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrine Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1530891X24006669\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1530891X24006669","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

目的恶性肿瘤高钙血症是导致恶性肿瘤患者死亡的一个危险因素。虽然肿瘤细胞分泌的甲状旁腺激素相关蛋白(PTHrP)会诱发高钙血症,但血清PTHrP水平与死亡率之间的关系仍不清楚。方法我们纳入了高钙血症(>10 mg/dL)和 PTHrP 水平升高(>1.0 pmol/L)的患者,并分析了死亡率(癌症诊断后的总生存率、PTHrP 测量值和 5 年生存率)。此外,我们还使用 Cox 比例危险模型分析法研究了 PTHrP 水平对生存预后的影响,并评估了这种影响是否因钙浓度而异。中位 PTHrP 水平、校正钙水平和年龄分别为 5.5(3.0-10.6)pmol/L、12.5(11.5-13.4)mg/dl 和 70(61-76)岁。PTHrP 与血清钙水平呈显著线性相关(相关系数:0.06;95% 置信区间:0.039-0.081;t:5.69;P<0.001)。PTHrP水平最高组的生存率明显低于PTHrP水平最低组(危险比:1.68,95%置信区间:1.03-2.77,P=0.038)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Association Between Parathyroid Hormone-Related Peptide Levels and Mortality in Patients With Malignancy

Objective

Hypercalcemia of malignancy is a risk factor for mortality in patients with malignancies. Although the parathyroid hormone-related protein (PTHrP) secreted by tumor cells induces hypercalcemia, the association between serum PTHrP levels and mortality remains unclear. This study aimed to investigate the association between serum PTHrP levels and mortality in patients with malignancies.

Methods

We included patients with hypercalcemia (>10 mg/dL) and elevated PTHrP levels (>1.1 pmol/L) and analyzed mortality (overall survival after cancer diagnosis, PTHrP measurement, and 5-year survival rate). Moreover, using Cox proportional hazard model analysis, we investigated the impact of PTHrP levels on survival prognosis, assessing whether this effect varied depending on calcium concentration.

Results

We analyzed the data of 183 patients. The median PTHrP level, corrected calcium level, and age were 5.5 (3.0-10.6) pmol/L, 12.5 (11.5-13.4) mg/dl, and 70 (61-76) years, respectively. PTHrP was significantly and linearly associated with serum calcium levels (correlation coefficient, 0.06; 95% CI: 0.039-0.081, t: 5.69; P < .001). The group with the highest PTHrP levels had significantly worse survival rates than the group with the lowest PTHrP levels (hazard ratio: 1.68, 95% CI 1.03-2.77, P = .038).

Conclusion

This study showed an association between PTHrP and mortality in patients with malignancy after adjusting for serum calcium levels.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Endocrine Practice
Endocrine Practice ENDOCRINOLOGY & METABOLISM-
CiteScore
7.60
自引率
2.40%
发文量
546
审稿时长
41 days
期刊介绍: Endocrine Practice (ISSN: 1530-891X), a peer-reviewed journal published twelve times a year, is the official journal of the American Association of Clinical Endocrinologists (AACE). The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists.
期刊最新文献
Under-resourced youth with diabetes in a community-based intervention show improved diabetes outcomes, technology use, and psychosocial functioning. Corrigendum to "Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study" [Endocrine Practice 30 (2024) 424-430]. Delivery Mode and Neonatal Thyrotropin Levels: Insights from a Systematic Review and Meta-Analysis. Continuous Glucose Monitoring in Hospitalized Patients with Type 2 Diabetes: A Step Forward in Inpatient Glycemic Control. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: A Systematic Review and Meta-Analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1